Illidge, Timothy M
AffiliationDepartment of Oncology, University of Cambridge
MetadataShow full item record
AbstractRadiotherapy is a fundamental component of treatment for the majority of patients with cancer. In recent decades, technological advances have enabled patients to receive more targeted doses of radiation to the tumour, with sparing of adjacent normal tissues. There had been hope that the era of precision medicine would enhance the combination of radiotherapy with targeted anticancer drugs, however this ambition remains to be realised. In view of this lack of progress, the FDA-AACR-ASTRO Clinical Development of Drug-Radiotherapy Combinations Workshop was held in February 2018 to bring together stakeholders and opinion leaders from academia, clinical radiation oncology, industry, patient advocacy groups and the FDA in order to discuss challenges to introducing new drug-radiotherapy combinations to the clinic. This "Perspectives in Regulatory Science and Policy" article summarises the themes and action points that were discussed. Intelligent trial design is required to increase the number of studies which efficiently meet their primary outcomes; endpoints to be considered include local control, organ preservation and patient-reported outcomes. Novel approaches including immune-oncology or DNA repair inhibitor agents combined with radiotherapy should be prioritised. In this article, we focus on how the regulatory challenges associated with defining a new drug-radiotherapy combination can be overcome in order to improve clinical outcomes for patients with cancer.
CitationAhmad S, Crittenden M, Tran P, Kluetz P, Blumenthal G, Bulbeck H, et al. Clinical development of novel drug-radiotherapy combinations. Clin Cancer Res. 2018 Nov 29.
JournalClin Cancer Res
- Clinical development of new drug-radiotherapy combinations.
- Authors: Sharma RA, Plummer R, Stock JK, Greenhalgh TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, Brown SR, Buckland S, Bulbeck H, Chalmers AJ, Clack G, Cranston AN, Damstrup L, Ferraldeschi R, Forster MD, Golec J, Hagan RM, Hall E, Hanauske AR, Harrington KJ, Haswell T, Hawkins MA, Illidge T, Jones H, Kennedy AS, McDonald F, Melcher T, O'Connor JP, Pollard JR, Saunders MP, Sebag-Montefiore D, Smitt M, Staffurth J, Stratford IJ, Wedge SR, NCRI CTRad Academia-Pharma Joint Working Group.
- Issue date: 2016 Oct
- Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop.
- Authors: Marciscano AE, Walker JM, McGee HM, Kim MM, Kunos CA, Monjazeb AM, Shiao SL, Tran PT, Ahmed MM
- Issue date: 2018 Jan 29
- Radiation-Drug Combinations to Improve Clinical Outcomes and Reduce Normal Tissue Toxicities: Current Challenges and New Approaches: Report of the Symposium Held at the 63rd Annual Meeting of the Radiation Research Society, 15-18 October 2017; Cancun, Mexico.
- Authors: Falls KC, Sharma RA, Lawrence YR, Amos RA, Advani SJ, Ahmed MM, Vikram B, Coleman CN, Prasanna PG
- Issue date: 2018 Oct
- Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme.
- Authors: Milas L, Mason KA, Crane CH, Liao Z, Masferrer J
- Issue date: 2003 May
- Personalized radiotherapy: concepts, biomarkers and trial design.
- Authors: Ree AH, Redalen KR
- Issue date: 2015 Jul